India, May 18 -- A recent study conducted over seven years has streamlined the testing and diagnosis of newborns with severe combined immunodeficiency (SCID), facilitating early intervention and treatment of infants before the development of symptoms.
The U.S. National Institute of Health (NIH) defines SCID as a rare group of genetic disorders that impair the functioning of infection-fighting immune cells. Individuals with SCID show little to no defense against pathogenic agents, making them highly susceptible to infections on even the slightest exposure to antigens. While newborn babies do not exhibit any obvious symptoms of the disorder, the condition is fatal if not treated within the first two or three years of life.
There are over 46...